• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.

作者信息

Athyros Vasilios G, Katsiki Niki, Tentolouris Nikolaos

机构信息

Second Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippocration Hospital, Thessaloniki, Greece.

出版信息

Curr Vasc Pharmacol. 2016;14(5):469-473. doi: 10.2174/1570161114666160909161537.

DOI:10.2174/1570161114666160909161537
PMID:27633290
Abstract
摘要

相似文献

1
Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial.社论：某些胰高血糖素样肽-1受体激动剂（GLP-1 RA）能否降低2型糖尿病的大血管并发症——关于利拉鲁肽在糖尿病中的疗效和作用：心血管结局结果评估（LEADER）试验的评论
Curr Vasc Pharmacol. 2016;14(5):469-473. doi: 10.2174/1570161114666160909161537.
2
Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.胰高血糖素样肽-1受体激动剂与心血管疾病：从LEADER研究到EXSCEL研究
Cardiovasc Res. 2018 Aug 1;114(10):e70-e71. doi: 10.1093/cvr/cvy124.
3
[Results of the LEADER study: current evidence and perspectives in research].[LEADER研究结果：当前研究证据与展望]
G Ital Cardiol (Rome). 2016 Dec;17(12 Suppl 2):28S-31. doi: 10.1714/2616.26913.
4
Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.使用风险比的替代指标评估 2 型糖尿病患者使用胰高血糖素样肽 1 受体激动剂的心血管风险。
Ann Pharmacother. 2018 Jul;52(7):632-638. doi: 10.1177/1060028018757407. Epub 2018 Feb 9.
5
Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review.GLP-1 激动剂在 2 型糖尿病中的心血管获益：比较综述。
Clin Sci (Lond). 2018 Aug 16;132(15):1699-1709. doi: 10.1042/CS20171299.
6
Use of GLP-1 RAs in Cardiovascular Disease Prevention: A Practical Guide.胰高血糖素样肽-1受体激动剂在心血管疾病预防中的应用：实用指南
Circulation. 2018 May 22;137(21):2200-2202. doi: 10.1161/CIRCULATIONAHA.117.032759.
7
GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?胰高血糖素样肽-1受体作为糖尿病视网膜病变治疗靶点：是福是祸？
Diabetes. 2017 Jun;66(6):1453-1460. doi: 10.2337/db16-1364.
8
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的心血管作用和临床结局。
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
9
[SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?].2型糖尿病合并心血管疾病患者使用钠-葡萄糖协同转运蛋白2抑制剂还是胰高血糖素样肽-1受体激动剂？
Rev Med Liege. 2018 Jan;73(1):43-50.
10
Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.胰高血糖素样肽1（GLP-1）受体激动剂对2型糖尿病患者脂肪分布的短期影响：一项超声检查研究
Acta Diabetol. 2015 Aug;52(4):727-32. doi: 10.1007/s00592-014-0710-z. Epub 2015 Jan 11.

引用本文的文献

1
Obesity in Adults: Position Statement of Polish Association for the Study on Obesity, Polish Association of Endocrinology, Polish Association of Cardiodiabetology, Polish Psychiatric Association, Section of Metabolic and Bariatric Surgery of the Association of Polish Surgeons, and the College of Family Physicians in Poland.成年人肥胖：波兰肥胖研究协会、波兰内分泌学会、波兰心脏糖尿病学会、波兰精神病学协会、波兰外科医师协会代谢与减重外科分会以及波兰家庭医师学院的立场声明。
Nutrients. 2023 Mar 28;15(7):1641. doi: 10.3390/nu15071641.
2
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.二肽基肽酶-4 抑制剂、胰高血糖素样肽 1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂用于心血管疾病患者：一项网状荟萃分析。
Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2.
3
Leptin, cardiovascular diseases and type 2 diabetes mellitus.瘦素、心血管疾病和 2 型糖尿病。
Acta Pharmacol Sin. 2018 Jul;39(7):1176-1188. doi: 10.1038/aps.2018.40. Epub 2018 Jun 7.
4
Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events.基于终点事件评估2型糖尿病患者中降糖药物对心血管益处的非血糖效应的糖化血红蛋白降低切点
Int J Endocrinol. 2018 Apr 19;2018:8457538. doi: 10.1155/2018/8457538. eCollection 2018.